The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I study of the safety and immunogenicity of a multi-peptide personalized genomic vaccine in the adjuvant treatment of solid tumors and hematological malignancies.
 
Ana Blazquez
No Relationships to Disclose
 
Alex Rubinsteyn
No Relationships to Disclose
 
Julia Kodysh
No Relationships to Disclose
 
John Patrick Finnigan
Employment - Crystal Run Healthcare (I)
Stock and Other Ownership Interests - Crystal Run Healthcare (I)
 
Thomas Urban Marron
No Relationships to Disclose
 
Marcia Meseck
No Relationships to Disclose
 
Timothy O'Donnell
No Relationships to Disclose
 
Jeffrey Hammerbacher
No Relationships to Disclose
 
Michael J. Donovan
No Relationships to Disclose
 
Milind Mahajan
No Relationships to Disclose
 
Brett A. Miles
Research Funding - Advaxis (Inst); MiMedx (Inst)
 
Hanna Irie
Research Funding - Cynvenio Biosystems
 
Amy Tiersten
Honoraria - Amgen; Tesaro
Consulting or Advisory Role - AstraZeneca; Eisai; Immunomedics; Novartis; Puma Biotechnology; Roche/Genentech
Speakers' Bureau - Amgen; tesaro
Research Funding - AstraZeneca; pfizer
Travel, Accommodations, Expenses - Amgen; tesaro
 
Ashutosh Tewari
No Relationships to Disclose
 
Samir S. Parekh
No Relationships to Disclose
 
Sujit Nair
No Relationships to Disclose
 
Matt D. Galsky
Stock and Other Ownership Interests - Rappta Therapeutics
Consulting or Advisory Role - Aileron Therapeutics; Astellas Pharma; AstraZeneca; BioMotiv; Bristol-Myers Squibb; Dendreon; Dracen; EMD Serono; Genentech; GlaxoSmithKline; Incyte; Inovio Pharmaceuticals; Janssen; Lilly; Merck; Novartis; NuMab; Pfizer; Seagen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792
 
Eric E. Schadt
No Relationships to Disclose
 
Philip Adam Friedlander
Stock and Other Ownership Interests - allergan; Avalanche Biotechnologies; Bristol-Myers Squibb; Clovis Oncology; Incyte; Merrimack
Consulting or Advisory Role - Array BioPharma; Aspyrian Therapeutics; Castle Biosciences; Genentech; regeneron; Seagen
Travel, Accommodations, Expenses - Array BioPharma; Castle Biosciences; Regeneron; Seagen
 
Nina Bhardwaj
Consulting or Advisory Role - Avidea Technologies; Checkpoint Sciences; CureVac; Neon Therapeutics; PrimeVax; Tempest Therapeutics
Research Funding - Celldex; Genentech; Ludwig Institute for Cancer Research; Novocure; Oncovir; Parker Institute for Cancer Immunotherapy